Raily Aesthetic Medicine International Holdings Full Year 2023 Earnings: CN¥0.078 loss per share (vs CN¥0.038 loss in FY 2022)

Raily Aesthetic Medicine International Holdings (HKG:2135) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥189.4m (up 15% from FY 2022).
• Net loss: CN¥32.5m (loss widened by 104% from FY 2022).
• CN¥0.078 loss per share (further deteriorated from CN¥0.038 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Raily Aesthetic Medicine International Holdings shares are down 14% from a week ago.

Risk Analysis

Don't forget that there may still be risks. For instance, we've identified 4 warning signs for Raily Aesthetic Medicine International Holdings (1 is significant) you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.